Patented cargo loading and surface functionalization methods enabling safe, repeatable delivery of genetic medicines to previously unreachable tissues — including the brain.
Of ~8,000 identified genetic diseases, only ~5% have approved treatments. The rest remain untreatable — not because we lack therapies, but because we cannot deliver them.
No re-dosing possible, immunogenic response
Liver-only targeting, poor CNS penetration
Invasive intrathecal delivery required
Proprietary cargo loading and surface functionalization methods that solve the two key bottlenecks in nanovesicle-based gene therapy.
Our proprietary cargo loading and functionalization methods overcome key limitations of current delivery technologies.
| Feature | AAV | LNP | BioPlatform |
|---|---|---|---|
| BBB Penetration | Moderate | Poor | Excellent |
| Repeat Dosing | No | Yes | Yes |
| Immunogenicity | High | Moderate | No |
| Cargo Loading Efficiency | Low | Moderate | 650x improved |
| IV Administration | Yes | Yes | Yes |
Advancing multiple programs across CNS and liver indications.
| Indication | Platform | Stage | Status |
|---|---|---|---|
| Huntington's Disease | BP-2 Hybrid | Preclinical Planning | LEAD PROGRAM |
| Hepatitis B | BP-2 Hybrid | PoC in Mouse | Method Patent Mar 2026 |
| Hepatitis D | BP-1 EMNV | PoC Complete | Seeking Licensee |
| APOL1 Kidney Disease | BP-2 Hybrid | Research | Back-up Indication |
Interested in partnership opportunities, licensing discussions, or investment? We'd love to hear from you.